RUBICON RESEARCH (RUBICON) Share Price falls 2.25% as stock closes lower today

Published:   22 September 2026 at 1:19:06 PM IST

Rubicon Research Share Price fell to Rs 1,692.30 today, down 2.25% from the previous close, while the company’s market capitalisation stood at Rs 29,030.99 crore. The move places Rubicon Research in the spotlight for investors tracking Rubicon Research Share Price Today, Rubicon Research Stock News and the day’s price action in the healthcare space. The data confirms a clear share price fall, but it does not establish a company-specific catalyst. What it does show is a large-cap pharmaceutical stock trading at a high valuation, with the market cap, P/E ratio and P/B ratio all remaining central to the Rubicon Research Share Price debate. For readers following Rubicon Research Share News on Univest, the key question is how today’s decline fits into the broader stock performance picture.

RUBICON RESEARCH (RUBICON) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,692.3
Previous Close	Rs 1,731.3
Today's Move	-Rs 39.00 (-2.25%)
Open	Rs 1,730.25
High	Rs 1,730.25
Low	Rs 1,684.55
Turnover	Rs 1.99 crore
Market Capitalisation	Rs 29,030.99 crore
Market Cap Category	Large Cap

Rubicon Research Share Price Today reflects a lower close at Rs 1,692.30 versus the previous close of Rs 1,731.30, which means the stock ended Rs 39.00 lower on the day. The session opened at Rs 1,730.25, matched the day’s high at Rs 1,730.25 and slipped to a low of Rs 1,684.55. That range shows a session that began near the previous close and finished closer to the day’s low. The turnover stood at Rs 1.99 crore. Since the company is classified as a Large Cap in the supplied data, today’s Rubicon Research Share Price Fall is best read as a large-cap price event within the pharmaceuticals segment, rather than as a standalone story about size. The move also matters for Rubicon Research Share Price Live searches because it gives a full snapshot of current price, day change, open, high, low and traded value. On the day, the stock’s decline was measured and factual, with no verified company-specific catalyst in the supplied information.

RUBICON RESEARCH (RUBICON) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 29,030.99 crore
P/E Ratio	99.43x
P/B Ratio	21.35x
ROE	27.84%
ROCE	29.22%
EPS	Rs 17.41
Book Value Per Share	Rs 81.09
Dividend Yield	0.09%

The Rubicon Research Share Price sits against a market capitalisation of Rs 29,030.99 crore, a P/E ratio of 99.43 and a P/B ratio of 21.35. These figures place valuation at the center of Rubicon Research Fundamental Analysis and Rubicon Research Stock Analysis. The company’s ROE is 27.84% and ROCE is 29.22%, both indicating strong returns on equity and capital employed relative to the valuation profile. EPS is Rs 17.41, and book value is Rs 81.09 per share, which helps frame how much accounting net worth backs each share. Dividend yield is 0.09%, which is a factual historical/current payout measure and should be read as such. In simple terms, the Rubicon Research Share Price is supported by profitability ratios that are meaningfully above many peer benchmarks, while the valuation multiples are also well above the industry medians shown later. That mix is central to Rubicon Research Financial Results and Rubicon Research Share Price Update searches, because it puts earnings quality and valuation in the same frame. For Univest readers, the fundamentals do not explain today’s decline by themselves; they provide the backdrop against which Rubicon Research Company News and Rubicon Research Latest News are being followed.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	99.43x
Benchmark Median P/E	32.62x
Benchmark Average P/E	49.51x
Benchmark P/E Range	3.37x to 747.32x
Company P/B Ratio	21.35x
Benchmark Median P/B	3x
Benchmark Average P/B	4.35x
Company ROE	27.84%
Benchmark Median ROE	11.74%
Benchmark Average ROE	10.79%
Company ROCE	29.22%
Benchmark Median ROCE	13.63%
Benchmark Average ROCE	13.4%
Company Market Capitalisation	Rs 29,030.99 crore
Benchmark Median Market Cap	Rs 746.45 crore
Benchmark Average Market Cap	Rs 14,202.67 crore

Rubicon Research belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. In the supplied benchmark scope of the same industry, covering 200 companies, the company’s P/E of 99.43 is above the benchmark median of 32.62 and above the benchmark average of 49.51. Its P/B of 21.35 is also above the benchmark median of 3.00 and benchmark average of 4.35. ROE at 27.84% is above the benchmark median of 11.74% and average of 10.79%, while ROCE at 29.22% is above the benchmark median of 13.63% and average of 13.40%. The benchmark market capitalisation median is Rs 746.45 crore and the average is Rs 14,202.67 crore, while Rubicon Research’s own market cap is Rs 29,030.99 crore, which places it above both reference points. This sector and industry comparison gives Rubicon Research Share Price Today an important valuation lens: the company is larger than the median industry stock and trades on richer multiples than the benchmark range. For Rubicon Research Stock News readers, that contrast is often more important than the day’s decline itself. The company’s performance also needs to be read alongside the broader Healthcare sector setting, where valuation dispersion remains wide across listed pharmaceuticals names.

Within the same industry benchmark, the company’s P/E of 99.43 sits below Divi’s Laboratories at 85.60? No, the supplied numbers show Rubicon Research above Divi’s Laboratories on P/E, and also above Torrent Pharmaceuticals at 86.64, Sun Pharmaceutical Industries at 37.05, Zydus Lifesciences at 25.67, Cipla at 33.19, Aurobindo Pharma at 26.61, Lupin at 17.53, Dr. Reddy’s Laboratories at 31.14 and Mankind Pharma at 49.13. On P/B, Rubicon Research’s 21.35 is higher than Sun Pharmaceutical Industries at 5.18, Divi’s Laboratories at 14.18, Torrent Pharmaceuticals at 21.05, Zydus Lifesciences at 4.30, Cipla at 3.18, Aurobindo Pharma at 2.54, Lupin at 4.07, Dr. Reddy’s Laboratories at 2.63 and Mankind Pharma at 5.96. Its ROE of 27.84% is above all the listed peer ROE figures supplied, and its ROCE of 29.22% is also above the listed peer ROCE figures supplied. That peer context is important for anyone scanning Rubicon Research Share Price News, because the stock’s valuation is not being viewed in isolation.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,40,397.93	37.05	5.18	14.85	19.11
Divi's Laboratories	DIVISLAB	2,48,664.42	85.6	14.18	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,82,738.23	86.64	21.05	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,012.19	25.67	4.3	19.69	21.39
Cipla	CIPLA	1,10,793.75	33.19	3.18	11.83	16

Among the supplied peers, Rubicon Research’s market capitalisation of Rs 29,030.99 crore is below Sun Pharmaceutical Industries at Rs 4,40,397.93 crore, Divi’s Laboratories at Rs 2,48,664.42 crore and Torrent Pharmaceuticals at Rs 1,82,738.23 crore, but above Zydus Lifesciences at Rs 1,15,012.19 crore and Cipla at Rs 1,10,793.75 crore. Its P/E of 99.43 is higher than all listed peers in the supplied set, including Laurus Labs at 99.72 only narrowly above the company’s own level. The P/B ratio of 21.35 is also higher than the peer values shown, except that it is close to Torrent Pharmaceuticals at 21.05. On profitability, Rubicon Research’s ROE of 27.84% and ROCE of 29.22% exceed the peer set provided. For Rubicon Research Share Price, this creates a clear contrast between strong return metrics and expensive valuation when compared with the peer basket. That contrast is central to Rubicon Research Stock Performance discussions on Univest and to anyone comparing Rubicon Research with other Pharmaceuticals & Drugs names.

Why Investors Are Watching Rubicon Research

• Rubicon Research Share Price fell 2.25% today to Rs 1,692.30.
• The stock closed Rs 39.00 below the previous close of Rs 1,731.30.
• Market capitalisation stood at Rs 29,030.99 crore, with a Large Cap classification.
• P/E was 99.43 and P/B was 21.35, both above the industry benchmark shown.
• ROE of 27.84%, ROCE of 29.22%, EPS of Rs 17.41 and book value of Rs 81.09 are key numbers in the current Rubicon Research Share Price debate.

About Rubicon Research

Rubicon Research operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data identifies the company within the listed pharma universe and positions it as a Large Cap stock by market-cap category. The key reported financial markers for Rubicon Research Share Price readers are market capitalisation of Rs 29,030.99 crore, EPS of Rs 17.41, book value of Rs 81.09 and dividend yield of 0.09%. In today’s Rubicon Research Stock News flow, the company is being followed mainly through valuation, profitability and sector comparison rather than through any newly stated company event.

Track Rubicon Research Share Price on Univest

Use RUBICON RESEARCH (RUBICON) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

On Univest, investors can track Rubicon Research Share Price, Rubicon Research Share Price Today, Rubicon Research Share News and Rubicon Research Stock Analysis in one place. The platform also helps users review financial ratios, shareholding pattern, 52-week levels and broader market insights for better context. For Rubicon Research Share Price Live monitoring, Univest brings the company’s key metrics together in a single research view.

Frequently Asked Questions

Why did Rubicon Research Share Price fall today?

Ans.  Rubicon Research Share Price fell 2.25% to Rs 1,692.30. The supplied data confirms the price event, but it does not identify a company-specific catalyst or trigger for the decline. The previous close was Rs 1,731.3.

What was Rubicon Research Share Price Today’s close?

Ans.  Rubicon Research Share Price Today closed at Rs 1,692.30, down Rs 39.00 from the previous close of Rs 1,731.30. The day’s open was Rs 1,730.25. The previous close was Rs 1,731.3.

What is Rubicon Research’s market capitalisation?

Ans.  Rubicon Research’s market capitalisation is Rs 29,030.99 crore. The data classifies the company as Large Cap, which places it above the benchmark industry median market cap of Rs 746.45 crore.

How does Rubicon Research compare on valuation?

Ans.  Rubicon Research Share Price sits alongside a P/E of 99.43 and a P/B of 21.35. Both are above the industry benchmark medians of 32.62 and 3.00 respectively, according to the supplied sector snapshot.

What do Rubicon Research’s ROE and ROCE show?

Ans.  Rubicon Research reports ROE of 27.84% and ROCE of 29.22%. Both figures are above the industry benchmark median and average in the supplied Pharmaceuticals & Drugs comparison set. ROE stands at 27.84%.

How does Rubicon Research compare with peers?

Ans.  Compared with peers such as Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals and Zydus Lifesciences, Rubicon Research has higher P/E and P/B multiples, while its ROE and ROCE are also stronger in the supplied set.

What is Rubicon Research’s EPS and book value?

Ans.  Rubicon Research reports EPS of Rs 17.41 and book value of Rs 81.09 per share. EPS shows earnings attributable to each share, while book value shows the accounting net worth behind each share.

Which sector and industry does Rubicon Research belong to?

Ans.  Rubicon Research belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. That sector context matters for Rubicon Research Share Price because the valuation benchmark is taken from the same industry.